表皮生長(zhǎng)因子受體(EGFR)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法)
ELISA Kit for Epidermal Growth Factor Receptor (EGFR)
ErbB-1; ErbB1; ER1; ERB-B1; MENA; HER1; Erythroblastic Leukemia Viral(v-Erb-B)oncogene Homolog,Avian; Proto-oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1
- 編號(hào)SEA757Hu
- 物種Homo sapiens (Human，人)相同的名稱，不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長(zhǎng)3h
- 檢測(cè)范圍3.12-200ng/mL
- 靈敏度最小可檢測(cè)劑量小于等于1.21ng/mL.
- 樣本類型serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載英文說明書 中文說明書
- 規(guī)格48T96T96T*596T*1096T*100
- 價(jià)格¥ 2386¥ 3408¥ 15336¥ 28968¥ 238560
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
產(chǎn)品包裝(模擬)
產(chǎn)品包裝(模擬)
實(shí)驗(yàn)結(jié)果圖
標(biāo)準(zhǔn)曲線圖
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測(cè)表皮生長(zhǎng)因子受體(EGFR)，經(jīng)檢測(cè)與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制，不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè)，因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的表皮生長(zhǎng)因子受體(EGFR)（加標(biāo)樣品），重復(fù)測(cè)定并計(jì)算其均值，回收率為測(cè)定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 94-101 | 97 |
| EDTA plasma(n=5) | 93-101 | 97 |
| heparin plasma(n=5) | 99-105 | 102 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定，每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的表皮生長(zhǎng)因子受體(EGFR)，并倍比稀釋成1:2，1:4，1:8，1:16的待測(cè)樣本，線性范圍即為稀釋后樣本中表皮生長(zhǎng)因子受體(EGFR)含量的測(cè)定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 80-93% | 87-94% | 81-88% | 92-102% |
| EDTA plasma(n=5) | 78-101% | 92-101% | 80-94% | 85-94% |
| heparin plasma(n=5) | 85-92% | 87-96% | 81-94% | 95-103% |
穩(wěn)定性
經(jīng)測(cè)定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品及樣本）100µL，37°C孵育1小時(shí)；
3. 吸棄，加檢測(cè)溶液A100µL，37°C孵育1小時(shí)；
4. 洗板3次；
5. 加檢測(cè)溶液B100µL，37°C孵育30分鐘；
6. 洗板5次；
7. 加TMB底物90µL，37°C孵育10-20分鐘；
8. 加終止液50µL，立即450nm讀數(shù)。
實(shí)驗(yàn)原理
將表皮生長(zhǎng)因子受體(EGFR)抗體包被于96孔微孔板中，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本，其中的表皮生長(zhǎng)因子受體(EGFR)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的表皮生長(zhǎng)因子受體(EGFR)抗體，將未結(jié)合的生物素化抗體洗凈后，加入HRP標(biāo)記的親和素，再次徹底洗滌后加入TMB底物顯色。TMB在過氧化物酶的催化下轉(zhuǎn)化成藍(lán)色，并在酸的作用下轉(zhuǎn)化成最終的黃色。顏色的深淺和樣品中的表皮生長(zhǎng)因子受體(EGFR)呈正相關(guān)。用酶標(biāo)儀在450nm波長(zhǎng)下測(cè)定吸光度(O.D.值)，計(jì)算樣品濃度。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| APA757Hu01 | 表皮生長(zhǎng)因子受體(EGFR)活性蛋白 | Cell?culture;?Activity?Assays. |
| APA757Hu02 | 表皮生長(zhǎng)因子受體(EGFR)活性蛋白 | Cell?culture;?Activity?Assays. |
| APA757Hu62 | 表皮生長(zhǎng)因子受體(EGFR)活性蛋白 | Cell?culture;?Activity?Assays. |
| RPA757Hu01 | 表皮生長(zhǎng)因子受體(EGFR)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| APA757Hu61 | 表皮生長(zhǎng)因子受體(EGFR)活性蛋白 | Cell?culture;?Activity?Assays. |
| EPA757Hu62 | 表皮生長(zhǎng)因子受體(EGFR)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPA757Hu02 | 表皮生長(zhǎng)因子受體(EGFR)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| EPA757Hu61 | 表皮生長(zhǎng)因子受體(EGFR)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAA757Hu06 | 表皮生長(zhǎng)因子受體(EGFR)多克隆抗體 | WB; IHC; ICC; IP. |
| PAA757Hu02 | 表皮生長(zhǎng)因子受體(EGFR)多克隆抗體 | WB; IHC; ICC; IP. |
| PAA757Hu01 | 表皮生長(zhǎng)因子受體(EGFR)多克隆抗體 | WB; IHC; ICC; IP. |
| FAA757Hu51 | 抗表皮生長(zhǎng)因子受體(EGFR)多克隆抗體(別藻藍(lán)蛋白標(biāo)記) | FCM |
| MAA757Hu27 | 表皮生長(zhǎng)因子受體(EGFR)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA757Hu29 | 表皮生長(zhǎng)因子受體(EGFR)單克隆抗體 | WB; IHC; ICC; IP. |
| RAA757Hu21 | 表皮生長(zhǎng)因子受體(EGFR)重組抗體 | WB; IF; ICC; IHC; IP; FCM. |
| MAA757Hu21 | 表皮生長(zhǎng)因子受體(EGFR)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA757Hu23 | 表皮生長(zhǎng)因子受體(EGFR)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA757Hu24 | 表皮生長(zhǎng)因子受體(EGFR)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA757Hu25 | 表皮生長(zhǎng)因子受體(EGFR)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA757Hu22 | 表皮生長(zhǎng)因子受體(EGFR)單克隆抗體 | WB; IHC |
| SEA757Hu | 表皮生長(zhǎng)因子受體(EGFR)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| HEA757Hu | 表皮生長(zhǎng)因子受體(EGFR)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,高敏型) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| AEA757Hu | 抗表皮生長(zhǎng)因子受體抗體(Anti-EGFR)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antibody Detection. |
| LMA757Hu | 表皮生長(zhǎng)因子受體(EGFR)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Thoracic Cancer | Nimotuzumab combined with gemcitabine and cisplatin as second-line chemotherapy for advanced non-small-cell lung cancer[Wiley: source] |
| J Cent Nerv Syst Dis.? | Increased Epidermal Growth Factor Receptor (EGFR) Associated with Hepatocyte Growth Factor (HGF) and Symptom Severity in Children with Autism …[Pubmed:25249767] |
| Mol Cancer Ther | GC1118, an anti-EGFR antibody with a distinct binding epitope and superior inhibitory activity against high-affinity EGFR ligands[PubMed: 26586721] |
| Cell Death Dis.? | LINC01225 promotes occurrence and metastasis of hepatocellular carcinoma in an epidermal growth factor receptor-dependent pathway[Pubmed:26938303] |
| analytica chimica acta | Microfluidic immunosensor based on mesoporous silica platform and CMK-3/poly-acrylamide-co-methacrylate of dihydrolipoic acid modified gold electrode for cancer biomarker detection.[pubmed:28335979] |
| Talanta | EGFR detection in extracellular vesicles of breast cancer patients through immunosensor based on silica-chitosan nanoplatform[Doi: 10.1016/j.talanta.2018.10.016] |
| Bioorganic Chemistry | Design, synthesis, molecular docking and biological activity evaluation of some novel indole derivatives as potent anticancer active agents and apoptosis inducers[Pubmed: 30665034] |
| Journal of?enzyme?inhibition and medicinal chemistry | Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile[Pubmed: 30919701] |
| Bioorganic Chemistry | Design and synthesis of new benzoxazole/benzothiazole-phthalimide hybrids as antitumor-apoptotic agents[] |
| Bioorganic Chemistry | Synthesis and anticancer activity of bis-benzo [d][1, 3] dioxol-5-yl thiourea derivatives with molecular docking study[Pubmed: 31288134] |
| Oxidative Medicine and Cellular Longevity | Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters?…[Pubmed: 31737175] |
| Neoplasia | Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine[Pubmed: 33212364] |
| Association between Serum Epidermal Growth Factor Receptor and Cyclooxygenase-2 Levels in Patients with Non-small Cell Carcinoma of Lung[] | |
| Synthesis, EGFR-TK inhibition and anticancer activity of new quinoxaline derivatives[] | |
| IMMUNOLOGIC RESEARCH | Humoral immune response to epidermal growth factor receptor in lung cancer[33495907] |
| European Journal of Medicinal Chemistry | Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M/HER2 inhibitors: Design, synthesis, structure¨Cactivity relationship and biological activity as potential antitumor and anticonvulsant agents[33545637] |
| Journal of Molecular Structure | Design, synthesis, antiproliferative evaluation, and molecular docking study of new quinoxaline derivatives as apoptotic inducers and EGFR inhibitors[] |
| ACS Appl Mater Interfaces | Emitter–Quencher Pair of Single Atomic Co Sites and Monolayer Titanium Carbide MXenes for Luminol Chemiluminescent Reactions[34914377] |
| Bioorganic Chemistry | Discovery of new pyrimido [5, 4-c] quinolines as potential antiproliferative agents with multitarget actions: Rapid synthesis, docking, and ADME studies[Pubmed:35219045] |
